Prevention of Infection in the Perioperative Setting in Patients with Rheumatic Disease Treated with Immunosuppression
- 65 Downloads
Purpose of Review
Patients with autoimmune rheumatic disease are at increased risk of infection after surgery. The goal of this manuscript is to review current evidence on important contributors to infection risk in these patients and the optimal management of immunosuppression in the perioperative setting.
Recent studies have confirmed that patients with autoimmune rheumatic disease, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), are at increased risk of infection after surgery, with most evidence coming from studies of joint replacement surgery. Immunosuppression, disease activity, comorbidities, demographics, and surgeon and hospital volume are all important contributors to post-operative infection risk. Recently published guidelines regarding immunosuppression management before joint replacement recommend continuing the conventional disease-modifying drugs used to treat RA (e.g., methotrexate) without interruption, holding more potent conventional therapies for 1 week unless the underlying disease is severe, and holding biologic therapies for one dosing interval before surgery. Recent observational data suggests that holding biologics may not have a substantial impact on infection risk. These data also implicate glucocorticoids as a major contributor to post-operative infection risk.
Observational data supports recent recommendations to continue many therapies in the perioperative period with only short interruptions of biologics and other potent immunosuppression. Even brief interruptions may not significantly lower risk, although the field continues to evolve. Clinicians should also consider other risk factors and should focus on minimizing glucocorticoids before surgery when possible to limit the risk of post-operative infection.
KeywordsAutoimmune disease Surgery Immunosuppression Disease modifying anti-rheumatic drugs Infection Perioperative management
Michael George is supported by the Rheumatology Research Foundation Scientist Development Award and the National Institute of Arthritis and Musculoskeletal and Skin Diseases K23-AR073931-01. Joshua Baker has been supported by a VA Clinical Science Research & Development Career Development Award (IK2 CX000955) and Merit Award (I01 CX001703). The contents of this work do not represent the views of the Department of the Veterans Affairs or the US Government.
Compliance with Ethical Standards
Conflict of Interest
Dr. Michael George reports consultancy for AbbVie and grants from Bristol-Myers Squibb. Dr. Joshua Baker reports consultancy for Bristol-Myers Squibb and expert testimony for Burns White LLC.
Michael George has received a research grant from Bristol-Myers Squibb and consulting fees < $10,000 from AbbVie. Joshua Baker has received consulting fees < $10,000 from Bristol-Myers Squibb.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.• Cordtz RL, Hawley S, Prieto-Alhambra D, Højgaard P, Zobbe K, Overgaard S, et al. Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers. Ann Rheum Dis. 2018;77:684–9 Interrupted time-series using Danish registries showing that rates of total knee and hip replacement have decreased in RA in the era of biologic therapy but still remain substantially higher than for the general population.CrossRefGoogle Scholar
- 3.•• Ravi B, Croxford R, Austin PC, Hollands S, Paterson JM, Bogoch E, et al. Increased surgeon experience with rheumatoid arthritis reduces the risk of complications following total joint arthroplasty: surgical experience performing TJA in RA is protective. Arthritis Rheumatol. 2014;66:488–96 Canadian administrative database study which found that surgeon experience with arthroplasty in RA patients (surgeon RA joint replacement volume) was more important than overall surgeon volume in predicting complications.CrossRefGoogle Scholar
- 4.Creuzot-Garcher CP, Mariet AS, Benzenine E, Daien V, Korobelnik J-F, Bron AM, et al. Is combined cataract surgery associated with acute postoperative endophthalmitis? A nationwide study from 2005 to 2014. Br J Ophthalmol. 2018:bjophthalmol-2018-312171.Google Scholar
- 8.•• Cordtz RL, Zobbe K, Højgaard P, Kristensen LE, Overgaard S, Odgaard A, et al. Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: a nationwide cohort study using Danish healthcare registers. Ann Rheum Dis. 2018;77:281–8 Study of joint replacement using linked Danish registries found greater risk of prosthetic joint infection in patients with RA vs. osteoarthritis; biologic use in RA was associated with a non-significant increase in risk, while disease activity and glucocorticoid use were strongly associated with infection risk.CrossRefGoogle Scholar
- 9.Ravi B, Croxford R, Hollands S, Paterson JM, Bogoch E, Kreder H, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis: increased risk of specific complications in TJA recipients with RA. Arthritis Rheumatol. 2014;66:254–63.CrossRefGoogle Scholar
- 12.• Salt E, Wiggins AT, Rayens MK, Morris BJ, Mannino D, Hoellein A, et al. Moderating effects of immunosuppressive medications and risk factors for post-operative joint infection following total joint arthroplasty in patients with rheumatoid arthritis or osteoarthritis. Semin Arthritis Rheum. 2017;46:423–9 Administrative data study identified RA, male gender, obesity, and prednisone use as risk factors for infection after arthroplasty.CrossRefGoogle Scholar
- 13.Kurdi AJ, Voss BA, Tzeng TH, Scaife SL, El-Othmani MM, Saleh KJ. Rheumatoid arthritis vs osteoarthritis: comparison of demographics and trends of joint replacement data from the nationwide inpatient sample. Am J Orthop. 2018;47.Google Scholar
- 15.• Schnaser EA, Browne JA, Padgett DE, Figgie MP, D’Apuzzo MR. Perioperative complications in patients with inflammatory arthropathy undergoing total hip arthroplasty. J Arthroplast. 2016;31:2286–90 Study using the Nationwide Inpatient Sample found increased rates of immediate complications after hip arthroplasty in patients with RA and SLE, with increased mortality in patients with SLE.CrossRefGoogle Scholar
- 16.Merayo-Chalico J, Gónzalez-Contreras M, Ortíz-Hernández R, Alcocer-Varela J, Marcial D, Gómez-Martín D. Total hip arthroplasty outcomes: an 18-year experience in a single center: is systemic lupus erythematosus a potential risk factor for adverse outcomes? J Arthroplast. 2017;32:3462–7.CrossRefGoogle Scholar
- 19.• Quintanilla-González L, Torres-Villalobos G, Hinojosa-Azaola A. Risk factors for development of early infectious and noninfectious complications in systemic lupus erythematosus patients undergoing major surgery. Lupus. 2018;27:1960–72 Retrospective single-center study including 191 patients with SLE undergoing major surgery found increased post-operative complications in patients with SLE, with risk factors for infection including prednisone use, anemia, hypoalbuminemia, and lymphopenia.CrossRefGoogle Scholar
- 20.•• Lin J-A, Liao C-C, Lee Y-J, Wu C-H, Huang W-Q, Chen T-L. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann Rheum Dis. 2014;73:1646–51 Taiwanese study including 4321 patients with SLE undergoing major surgery demonstrated increased pneumonia, septicemia, and mortality in patients with SLE, with greater risk in patients with recent inpatient care for SLE or recent glucocorticoid injections.CrossRefGoogle Scholar
- 26.•• George MD, Baker JF, Hsu JY, Wu Q, Xie F, Chen L, et al. Perioperative timing of infliximab and the risk of serious infection after elective hip and knee arthroplasty. Arthritis Care Res (Hoboken). 2017;69:1845–54 Administrative claims study using Medicare data including 4288 patients receiving infliximab prior to total knee or hip arthroplasty found no significant difference in the risk of hospitalized infection or prosthetic joint infection in patients who continued infliximab vs. patients in whom infliximab was stopped before surgery; average glucocorticoid dose > 10 mg/day was associated with increased infection risk.CrossRefGoogle Scholar
- 28.Bozic KJ, Lau E, Kurtz S, Ong K, Rubash H, Vail TP, et al. Patient-related risk factors for periprosthetic joint infection and postoperative mortality following total hip arthroplasty in Medicare patients. The Journal of Bone and Joint Surgery (American). 2012 [cited 2015 Mar 6];94. Available from: https://doi.org/10.2106/JBJS.K.00072
- 33.• Tarabichi M, Shohat N, Kheir MM, Adelani M, Brigati D, Kearns SM, et al. Determining the threshold for HbA1c as a predictor for adverse outcomes after total joint arthroplasty: a multicenter, retrospective study. J Arthroplast. 2017;32:S263–S267.e1 Retrospective study of 1645 patients with diabetes undergoing arthroplasty found substantially higher rates of prosthetic joint infection in patients with higher hemoglobin A1c values.CrossRefGoogle Scholar
- 36.• Salt E, Wiggins AT, Rayens MK, Brown K, Eckmann K, Johannemann A, et al. Risk factors for transfusions following total joint arthroplasty in patients with rheumatoid arthritis. J Clin Rheumatol. 2018;24:422–6 Administrative data study found that patients with RA with a history of anemia were substantially more likely to receive a transfusion after total joint arthroplasty.CrossRefGoogle Scholar
- 37.• Katz JN, Losina E, Barrett J, Phillips CB, Mahomed NN, Lew RA, et al. Association between hospital and surgeon procedure volume and outcomes of total hip replacement in the United States Medicare population. J Bone Joint Surg Am. 2001;83-A:1622–9 Key older study using Medicare data showing the association between higher surgeon and hospital volume and improved outcomes after joint replacement.CrossRefGoogle Scholar
- 38.•• Goodman SM, Springer B, Guyatt G, Abdel MP, Dasa V, George M, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Rheumatol (Hoboken, NJ). 2017;69:1538–51 Guidelines from the American College of Rheumatology and American Association of Hip and Knee Surgeons providing recommendations for the management of immunosuppression in patients with RA and SLE undergoing total joint arthroplasty.CrossRefGoogle Scholar
- 41.Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014;CD000957.Google Scholar
- 47.Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatolgy Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018:annrheumdis-2017-212825.Google Scholar
- 48.Goodman SM, Menon I, Christos PJ, Smethurst R, Bykerk VP. Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. Rheumatology (Oxford). 2016;55:573–82.Google Scholar
- 50.• Abou Zahr Z, Spiegelman A, Cantu M, Ng B. Perioperative use of anti-rheumatic agents does not increase early postoperative infection risks: a Veteran Affairs’ administrative database study. Rheumatol Int. 2015;35:265–72 Study using Veteran’s Administration data found that neither interruption of conventional DMARDs nor interruption of biologic therapy was associated with a decreased risk of post-operative infection.CrossRefGoogle Scholar
- 51.• George M, Baker J, Winthrop K, Alemao E, Chen L, Connolly S, et al. Timing of abatacept before elective arthroplasty and risk of post-operative outcomes. Arthritis Care Res. Accepted for publication. Administrative claims study including 1939 surgeries found that patients who received intravenous abatacept within 4 weeks of surgery had similar outcomes to patients in which abatacept was held for 4–8 weeks or more than 8 weeks before surgery.Google Scholar
- 52.• Latourte A, Gottenberg J-E, Luxembourger C, Pane I, Claudepierre P, Richette P, et al. Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry. Rheumatology (Oxford). 2017;56:629–37 French registry study showing no association between abatacept timing and post-operative complications among 263 patients undergoing surgery.Google Scholar
- 53.George M, Baker J, Winthrop K, Alemao E, Chen L, Connolly S, et al. Comparative risk of biologic therapies and risk of glucocorticoids in patients with rheumatoid arthritis undergoing elective arthroplasty. Presented at the European League Against Rheumatism annual meeting, June 2018. Ann Rheum Dis. 2018;77:163.Google Scholar
- 54.Momohara S, Hashimoto J, Tsuboi H, Miyahara H, Nakagawa N, Kaneko A, et al. Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol. 2013;23:440–9.CrossRefGoogle Scholar
- 56.• Lau C, Dubinsky M, Melmed G, Vasiliauskas E, Berel D, McGovern D, et al. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg. 2015;261:487–96 Study of patients with inflammatory bowel disease undergoing abdominal surgery found that infliximab levels ≥ 3 μg/mL were associated with increased post-operative infection risk in patients with Crohn’s disease but not in patients with ulcerative colitis; timing of infliximab was not available.CrossRefGoogle Scholar